Emmessar Biotech & Nutrition Ltd (EMMESSA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Emmessar Biotech & Nutrition Ltd on NSE and BSE, with an AI summary of each filing.
please refer attachment
Others (Uncategorized) · 02 Nov 2026, 8:36 pm
Emmessar Biotech Q2 FY27 Financial Results Emmessar Biotech & Nutrition published its unaudited financial results for the quarter ended 30th Sep'26. Total revenue reached ₹62.50 lakh, compared to ₹59.85 lakh in Q1 FY27 and ₹63.04 lakh in Q2 FY26. Total expenses stood at ₹45.24 lakh versus ₹43.55 lakh in the preceding quarter. Net profit after tax came in at ₹14.03 lakh, up slightly from ₹13.15 lakh in Q1 FY27 and ₹11.46 lakh in Q2 FY26. Basic and diluted EPS for the quarter was reported at ₹0.28.
Please refer attachment
Financial Result · 31 Oct 2026, 9:31 pm
Emmessar Biotech Q2 FY27 Results: PAT Rises 23% YoY to Rs 14.03 Lakh Emmessar Biotech & Nutrition reported revenue from operations of Rs 10.92 lakh for Q2 ended 30th Sep'26, up 19.1% YoY from Rs 9.17 lakh (Rs 5.93 lakh in Q1). Total income stood at Rs 62.50 lakh versus Rs 63.04 lakh YoY, supported by other income of Rs 51.58 lakh. PBT rose 23.1% YoY to Rs 17.26 lakh, while net profit grew 23.1% YoY to Rs 14.03 lakh from Rs 11.40 lakh. Basic and diluted EPS improved to Rs 0.28.
Please refer attachment.
Outcome · 31 Oct 2026, 9:25 pm
Emmessar Biotech & Nutrition Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 10.9 (+19.1% YoY | +84.1% QoQ) ■ EBITDA: -32.0 (+14.2% YoY | +9.4% QoQ) ■ EBITDA Margin (%): -293 (+11369 bps YoY | +30208 bps QoQ) ■ PAT: 14.0 (+23.1% YoY | +6.7% QoQ) ■ EPS (INR): 0.28 (+21.7% YoY | +7.7% QoQ) Emmessar Biotech & Nutrition Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) Segmental Performance Healthcare ■ Revenue: 10.9 (+19.1% YoY | +84.1% QoQ) ■ EBIT: 7.1 (+5.0% YoY | +72.3% QoQ) ■ EBIT Margin (%): 64.8 (-867 bps YoY | -447 bps QoQ) Rent on leasehold land ■ Revenue: 41.3 (+0.0% YoY | +0.0% QoQ) ■ EBIT: 41.1 (+0.0% YoY | +0.0% QoQ) ■ EBIT Margin (%): 99.4 (+0 bps YoY | +0 bps QoQ) Others ■ Revenue: 10.3 (-18.3% YoY | -18.6% QoQ) ■ EBIT: 10.3 (-18.3% YoY | -18.6% QoQ) ■ EBIT Margin (%): 100 (+0 bps YoY | +0 bps QoQ)
Emmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve Please refer attachment
Intimation · 31 Oct 2026, 5:30 am
Emmessar Biotech Schedules Board Meeting on 31st Oct'26 for Q2 Results Emmessar Biotech & Nutrition Limited has informed the BSE that a meeting of its Board of Directors is scheduled for 31st Oct'26 in Mumbai. The board will consider and approve the company's unaudited financial results for the quarter ended 30th Sep'26. Additionally, the trading window for dealing in the company's equity shares remains closed until 2nd Nov'26 pursuant to SEBI Prohibition of Insider Trading Regulations.
Please refer attachment
Others (Uncategorized) · 02 Oct 2026, 8:25 pm
Emmessar Biotech Reports Nil Physical Share Re-Lodgement Requests Emmessar Biotech & Nutrition published a newspaper advertisement on 2nd Oct'26 regarding a special window for re-lodging physical share transfer requests, pursuant to SEBI circulars dated 2nd Jul'25 and 30th Jan'26. The special window operates from 5th Feb'26 to 4th Feb'27 for transfer deeds lodged prior to 1st Apr'19 that were rejected or returned. The company confirmed that no re-lodgement requests have been received from shareholders, and its RTA, MUFG Intime India Private Limited, completed the mandatory regulatory reporting to SEBI.
Please refer attachement
Annual General Meeting · 29 Sept 2026, 6:58 pm
Emmessar Biotech 34th AGM Voting Results and Scrutinizer Report Emmessar Biotech & Nutrition Limited approved all four resolutions at its 34th AGM held on 29th Sep'26 with a 95.31% majority (1,595,343 votes in favour vs. 78,553 against; 33.50% total turnout). Key approvals include the adoption of FY26 audited financial statements, the re-appointment of Director Jeyavel Balaiah Nadar upon retirement by rotation, and 5-year re-appointments for Srinivasa Raghavan Mathurakavi Ayyangar as Managing Director and Jeyavel Balaiah Nadar as Whole-time Director. Entire promoter group voting (1,569,127 shares) unanimously supported all resolutions.
Please refer attachment
Annual General Meeting · 29 Sept 2026, 5:51 pm
Emmessar Biotech & Nutrition Concludes 34th Annual General Meeting Emmessar Biotech & Nutrition Limited conducted its 34th AGM on 29th Sep'26 via video conferencing. Key resolutions transacted included the adoption of audited financial statements for FY26, the re-appointment of retiring director Mr. Jeyavel Balaiah Nadar, and special resolutions approving five-year extensions for Managing Director Mr. Srinivasa Raghavan Mathurakavi Ayyangar and Whole-time Director Mr. Jeyavel Balaiah Nadar. Remote e-voting ran from 26th Sep'26 to 28th Sep'26, and final voting results will be disclosed within 48 hours following the scrutinizer's report.
Please refer attachment
Others (Uncategorized) · 05 Sept 2026, 4:35 pm
Emmessar Biotech Schedules 34th AGM and Issues Remote E-Voting Timeline Emmessar Biotech & Nutrition Limited has issued newspaper advertisements in *The Free Press Journal* and *Navashakti* confirming the dispatch of its 34th AGM notice and FY26 annual report to eligible shareholders. The AGM is scheduled for 29th Sep'26 via VC/OAVM. The cut-off date to determine shareholder voting eligibility is 22nd Sep'26. The remote e-voting window opens on 26th Sep'26 (09:00 AM IST) and concludes on 28th Sep'26 (05:00 PM IST), managed via MUFG Intime India (formerly Link Intime India).
Please refer attachment
Others (Uncategorized) · 04 Sept 2026, 11:46 pm
Emmessar Biotech Dispatches 34th AGM Notice and FY26 Annual Report Access Details Emmessar Biotech & Nutrition dispatched communications on 4th Sep'26 to shareholders without registered email addresses, providing web links to access the FY26 Annual Report and Notice for the 34th AGM. The AGM is scheduled for 29th Sep'26 at 10:30 AM via VC/OAVM. The remote e-voting window runs from 26th Sep'26 (9:00 AM) to 28th Sep'26 (5:00 PM), with a cut-off date of 22nd Sep'26. The company also urged physical shareholders to complete mandatory KYC updation and dematerialise their holdings.
Please refer attachment
Others (Uncategorized) · 04 Sept 2026, 11:22 pm
Emmessar Biotech Schedules 34th AGM and Issues Annual Report Access Notice Emmessar Biotech & Nutrition has dispatched communications to unregistered-email shareholders providing web links to access its FY26 Annual Report and 34th AGM notice. The AGM is scheduled for 29th Sep'26 at 10:30 AM via VC/OAVM. The cut-off date for e-voting eligibility is set for 22nd Sep'26, with remote e-voting running from 26th Sep'26 (9:00 AM) to 28th Sep'26 (5:00 PM). The company also urged physical shareholders to update mandatory KYC details and dematerialize shares per SEBI guidelines.
Please refer attachment
Others (Uncategorized) · 04 Sept 2026, 11:19 pm
Emmessar Biotech FY26 Financial Results and Annual General Meeting Notice Emmessar Biotech & Nutrition Ltd reported total income of Rs 240.65 Lakhs for FY26 versus Rs 261.96 Lakhs in FY25, with net profit after tax rising to Rs 43.57 Lakhs from Rs 31.62 Lakhs in FY25. Basic and diluted EPS improved to Rs 0.87 compared to Rs 0.63 in FY25. Revenue from operations stood at Rs 37.08 Lakhs, while lease rent generated Rs 165.31 Lakhs. The company convened its 34th AGM on 29th Sep'26, proposing five-year reappointments for key managerial personnel. No dividend was recommended.
Please refer attachment
Annual General Meeting · 04 Sept 2026, 11:15 pm
Emmessar Biotech 34th AGM Notice and Board Re-Appointments Emmessar Biotech & Nutrition Ltd. scheduled its 34th AGM for 29th Sep'26 via VC/OAVM. Key agenda items include adopting FY26 audited financial statements and approving executive re-appointments for 5-year terms. The company proposed re-appointing Srinivasa Raghavan Mathurakavi Ayyangar as MD (tenure 20th Apr'27 to 19th Apr'32) with monthly remuneration of ₹2.20 lakh–₹4.00 lakh, plus perquisites up to 50% of salary. Additionally, Jeyavel Balaiah Nadar is proposed for re-appointment as WTD/CFO (tenure 6th Feb'26 to 5th Feb'31) with monthly pay of ₹1.20 lakh–₹2.50 lakh. Remote e-voting runs 26th Sep'26 to 28th Sep'26.
Please refer attachment
Annual General Meeting · 27 Aug 2026, 8:10 pm
Emmessar Biotech to Hold 34th Annual General Meeting on Sep 29 Emmessar Biotech & Nutrition Ltd. (BSE: 530825) has announced its 34th Annual General Meeting (AGM) will be held via Video Conferencing (VC) on 29 Sep'26. In compliance with MCA and SEBI circulars, the AGM notice and Annual Report for FY25-26 will be dispatched electronically to shareholders. Shareholders who have not registered their email address or bank details are advised to do so with the company's registrar and transfer agent, MUFG Intime India Private Limited, to receive communications and participate in e-voting.
Please refer attachment
Others (Uncategorized) · 08 Aug 2026, 7:47 pm
Emmessar Biotech Publishes Q1 FY27 Financial Results Emmessar Biotech reported its audited financial results for the quarter ended Jun 30, 2026. Total income stood at ₹15.55 Lacs, down from ₹18.02 Lacs in Mar'26 and ₹51.67 Lacs in Jun'25. The company posted a Profit After Tax of ₹10.59 Lacs, compared to a profit of ₹17.12 Lacs in the preceding quarter and ₹45.67 Lacs in the same quarter last year. Earnings Per Share (EPS) for the quarter was ₹0.21. The results were published in the Free Press Journal and Nav Shakti on Aug 08, 2026.
Please refer attachement
Financial Result · 07 Aug 2026, 7:35 pm
Emmessar Biotech Q1 FY27 Net Profit Declines Amid Lower Revenue Emmessar Biotech reported a Q1 FY27 standalone net profit of ₹13.15 lakhs, a 23.2% YoY decline from ₹17.12 lakhs, despite a QoQ increase from ₹3.42 lakhs. Revenue from operations fell 36.1% YoY to ₹5.93 lakhs. Total income also decreased by 4.5% YoY to ₹59.85 lakhs. Profit before tax stood at ₹16.30 lakhs, down 29.5% YoY but up 104.8% QoQ. The Board approved these unaudited results on 07 Aug'26 and announced its 34th AGM for 29 Sep'25.
Please refer attachement
Outcome · 07 Aug 2026, 7:30 pm
Emmessar Biotech & Nutrition Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 5.9 (-36.1% YoY | -36.1% QoQ) ■ EBITDA: -35.3 (-27.2% YoY | +4.2% QoQ) ■ EBITDA Margin (%): -595 (-29602 bps YoY | -19828 bps QoQ) ■ PAT: 13.2 (-23.2% YoY | +284.5% QoQ) ■ EPS (INR): 0.26 (-23.5% YoY | +2500.0% QoQ) Emmessar Biotech & Nutrition Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) Segmental Performance Healthcare ■ Revenue: 5.9 (-36.1% YoY | -36.1% QoQ) ■ EBIT: 4.1 (-33.5% YoY | -32.5% QoQ) ■ EBIT Margin (%): 69.3 (+271 bps YoY | +368 bps QoQ) Rent on Leasehold Land ■ Revenue: 41.3 (+0.0% YoY | +0.0% QoQ) ■ EBIT: 41.1 (+0.0% YoY | +0.0% QoQ) ■ EBIT Margin (%): 99.4 (+0 bps YoY | +0 bps QoQ) Others ■ Revenue: 12.6 (+4.1% YoY | +109.5% QoQ) ■ EBIT: 12.6 (+4.1% YoY | +109.5% QoQ) ■ EBIT Margin (%): 100 (+0 bps YoY | +0 bps QoQ)
Emmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve please refer attachment
Intimation · 07 Aug 2026, 5:30 am
Emmessar Biotech Board Meeting Set for Aug 7 to Approve Q1FY27 Results Emmessar Biotech & Nutrition Ltd. scheduled a Board of Directors meeting for Aug 07, 2026, to consider and approve the unaudited financial results for the quarter ended Jun 30, 2026. In accordance with SEBI regulations, the trading window for the company's equity shares will remain closed until Aug 09, 2026.
please refer attachment
Others (Uncategorized) · 01 Aug 2026, 9:20 pm
Emmessar Biotech Informs on Re-lodgement of Physical Share Transfers Emmessar Biotech & Nutrition published a newspaper advertisement on 01 Aug'26, informing shareholders about the special window for re-lodgement of physical share transfer requests. This complies with SEBI Circular dated 30 Jan'26. The advertisement appeared in "The Free Press Journal" and "Navshakti". The company also confirmed, per a SEBI circular from 02 Jul'25, that no re-lodgement requests were received from shareholders, and its Registrar and Transfer Agent (RTA) has reported this to SEBI as required.
Please refer attachment
Others (Uncategorized) · 14 May 2026, 7:04 pm
Emmessar Biotech Informs on Re-lodgement of Physical Share Transfer Requests Emmessar Biotech & Nutrition has published a newspaper advertisement on 14 May'26, creating a special window for shareholders to re-lodge physical share transfer requests. This action complies with SEBI Circular dated 30 Jan'26. The company also noted that, per a SEBI Circular from 02 Jul'25, no re-lodgement requests for physical share transfers were previously received from shareholders. The necessary reporting has been completed with SEBI by the company's Registrar and Transfer Agent, MUFG Intime India Private Limited.
please refer attachment
Others (Uncategorized) · 13 May 2026, 10:40 pm
Emmessar Biotech Q4 & FY26 Financial Results Published Emmessar Biotech published its audited financial results for the quarter and year ended 31 Mar'26. For Q4FY26, Net Profit was ₹7.86 lakh versus ₹12.06 lakh QoQ and ₹25.85 lakh YoY. Total Income for the quarter stood at ₹45.87 lakh, down from ₹56.02 lakh QoQ and ₹98.76 lakh YoY. For the full year FY26, Net Profit was ₹42.47 lakh against ₹77.01 lakh in FY25, while FY26 Total Income was ₹252.88 lakh compared to ₹343.91 lakh in the previous year.
please refer attachement
Financial Result · 12 May 2026, 7:53 pm
EMMESSAR BIOTECH & NUTRITION LTD - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 9.3 (-3.0% YoY | -0.6% QoQ) ■ EBITDA: -36.8 (-13.6% YoY | -9.7% QoQ) ■ EBITDA Margin (%): -397 (-5821 bps YoY | -3734 bps QoQ) ■ PAT: 3.4 (Loss to Profit YoY | -70.6% QoQ) ■ EPS (INR): 0.01 (Loss to Profit YoY | -95.7% QoQ) EMMESSAR BIOTECH & NUTRITION LTD - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) Segmental Performance Healthcare ■ Revenue: 9.3 (-3.0% YoY | -0.6% QoQ) ■ EBIT: 6.1 (-3.8% YoY | +5.0% QoQ) ■ EBIT Margin (%): 65.6 (-52 bps YoY | +353 bps QoQ) Rent on Leasehold land ■ Revenue: 41.3 (+1.1% YoY | +0.0% QoQ) ■ EBIT: 41.1 (+1.1% YoY | +0.0% QoQ) ■ EBIT Margin (%): 99.4 (+1 bps YoY | +0 bps QoQ) Others ■ Revenue: 6.0 (-69.8% YoY | -21.4% QoQ) ■ EBIT: 6.0 (-69.8% YoY | -21.4% QoQ) ■ EBIT Margin (%): 100 (+0 bps YoY | +0 bps QoQ)
please refer attachment
Outcome · 12 May 2026, 7:47 pm
EMMESSAR BIOTECH & NUTRITION LTD - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 9.3 (-3.0% YoY | -0.6% QoQ) ■ EBITDA: -36.8 (-13.6% YoY | -9.7% QoQ) ■ EBITDA Margin (%): -397 (-5821 bps YoY | -3734 bps QoQ) ■ PAT: 3.4 (Loss to Profit YoY | -70.6% QoQ) ■ EPS (INR): 0.01 (Loss to Profit YoY | -95.7% QoQ) EMMESSAR BIOTECH & NUTRITION LTD - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) Segmental Performance Healthcare ■ Revenue: 9.3 (-3.0% YoY | -0.6% QoQ) ■ EBIT: 6.1 (-3.8% YoY | +5.0% QoQ) ■ EBIT Margin (%): 65.6 (-52 bps YoY | +353 bps QoQ) Rent on Leasehold land ■ Revenue: 41.3 (+1.1% YoY | +0.0% QoQ) ■ EBIT: 41.1 (+1.1% YoY | +0.0% QoQ) ■ EBIT Margin (%): 99.4 (+1 bps YoY | +0 bps QoQ) Others ■ Revenue: 6.0 (-69.8% YoY | -21.4% QoQ) ■ EBIT: 6.0 (-69.8% YoY | -21.4% QoQ) ■ EBIT Margin (%): 100 (+0 bps YoY | +0 bps QoQ)
Emmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve please refer attachement
Intimation · 12 May 2026, 5:30 am
Emmessar Biotech Board Meeting to Approve FY26 Results on May 12 Emmessar Biotech & Nutrition Ltd. (BSE: 524768) will hold a Board of Directors meeting on May 12, '26, to consider and approve the audited financial results for the year ended Mar 31, '26. In accordance with SEBI insider trading regulations, the trading window for the company's equity shares will remain closed until May 14, '26. The meeting will take place in Mumbai.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 08 Apr 2026, 10:37 pm
Emmessar Biotech Confirms It Is Not a Large Corporate Emmessar Biotech & Nutrition Ltd. informed the exchange on 08 Apr'26 that it does not qualify as a "Large Corporate" under SEBI's funding framework circular dated 19 Oct'23. Consequently, requirements such as mandatory borrowing and credit ratings are not applicable. The company reported NIL outstanding borrowings as of 31 Mar'25. This declaration clarifies its regulatory status and financial obligations under the specified SEBI framework, confirming it is exempt from the associated borrowing mandates for large-cap companies.
Please refer attachment
Others (Uncategorized) · 10 Mar 2026, 7:23 pm
Emmessar Biotech Publishes Notice on Physical Share Transfer Window Emmessar Biotech & Nutrition Ltd. announced on 10 Mar'26 it has published newspaper advertisements regarding a special window for the re-lodgement of transfer requests for physical shares, complying with a SEBI circular dated 30 Jan'26. The company also confirmed that, per a separate SEBI circular from 02 Jul'25, it received no requests for the re-lodgement of physical shares between Jul'25 and Jan'26. This has been reported to SEBI by the company's Registrar and Transfer Agent, MUFG Intime India Private Limited.